Patents by Inventor Antonio Ricci

Antonio Ricci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ethynyl derivatives
    Patent number: 11034699
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • COMPOUNDS
    Publication number: 20210079005
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS
    Publication number: 20210070739
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 11, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
    Patent number: 10882848
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 5, 2021
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • PROCESS FOR THE PREPARATION OF HIGH PURITY GLUCAGON
    Publication number: 20200399339
    Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 24, 2020
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI, Steve MCINTYRE, Alex SAUNDERS
  • BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR
    Publication number: 20200361930
    Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: August 4, 2020
    Publication date: November 19, 2020
    Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • BIFUNCTIONAL INHIBITORS WITH EGFR HAVING A E3 UBIQUITIN LIGASE MOIETY
    Publication number: 20200308171
    Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.
    Inventors: Georg Jaeschke, Bernd Kuhn, Antonio Ricci, Daniel Rueher, Sandra Steiner, Yvonne Alice Nagel, Martin Duplessis, Kiel Lazarski, Yanke Liang
  • ETHYNYL DERIVATIVES
    Publication number: 20200255440
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
  • PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES
    Publication number: 20200172577
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 4, 2020
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
  • COMPOUNDS
    Publication number: 20200102299
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of TMLR, TMLRCS, LR, LACS containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
  • Process for the preparation of sugammadex
    Patent number: 10577433
    Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 3, 2020
    Assignee: Fresenius Kabi iPSUM S.r.l.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Tapanjyoti Biswal, Nitin Kumar, Madan Singh
  • 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS
    Publication number: 20190308955
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • AN IMPROVED PROCESS FOR THE PREPARATION OF SUGAMMADEX
    Publication number: 20190284308
    Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.
    Type: Application
    Filed: March 20, 2017
    Publication date: September 19, 2019
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter CABRI, Antonio RICCI, Jacopo ZANON, Saswata LAHIRI, Govind SINGH, Shivaji Haribhau SHELKE, Tapanjyoti BISWAL, Nitin KUMAR, Madan SINGH
  • Crystalline forms of per-chloro-?-cyclodextrines
    Patent number: 10414830
    Abstract: The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-?-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-?-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: September 17, 2019
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Shridhar Reddy, Nitin Kumar, Madan Singh
  • Process for the preparation of sugammadex and its intermediates
    Patent number: 10414829
    Abstract: The present application provides an improved process for the preparation of sugammadex which comprises the halogenation of ?-cyclodextrin in a suitable organic solvent to give 6-per-deoxy-6-per-halo-?-cyclodextrin, wherein halo is bromo or chloro, reacting the halogenated ?-cyclodextrin with 3-mercaptopropionic acid in the presence of alkoxide base to obtain sugammadex of formula I. This application also provides isolation of 6-per-deoxy-6-per-chloro-?-cyclodextrin as a crystalline compound and its use for the preparation of sugammadex of formula (I).
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 17, 2019
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Dominik Heckmann
  • Process intermediates and methods for the preparation of process intermediates for the synthesis of argatroban monohydrate
    Patent number: 10385020
    Abstract: Methods are provided for the synthesis of key intermediates for the synthesis of Argatroban monohydrate, ethyl (2R,4R)-1-[(2S)-2-amino-5-[[imino(nitroamino)methyl]amino]-1-oxopentyl]-4-methylpiperidine-2-carboxylate compounded with HCl. Such intermediates are also provided.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: August 20, 2019
    Assignee: LUNDBECK PHARMACEUTICALS ITALY S.P.A.
    Inventors: Mariano Stivanello, Florian Anton Martin Huber, Antonio Ricci
  • ETHYNYL DERIVATIVES
    Publication number: 20190144458
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BARBARA BIEMANS, GEORG JAESCHKE, ANTONIO RICCI, DANIEL RUEHER, FIONN O'HARA
  • ETHYNYL DERIVATIVES
    Publication number: 20190119290
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Ethynyl derivatives
    Patent number: 10189848
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 29, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES
    Publication number: 20180362588
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: December 19, 2016
    Publication date: December 20, 2018
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI